![分析与化学品开发 分析与化学品开发](/cs/publishingimages/Chemical_Development_Oligo_Manufacturing.jpg)
产品详细信息
- 分析方法开发、确认和验证
- 化学工艺优化、放大和验证
- 广泛的寡核苷酸化合物产品组合,包括反义寡核苷酸、适配体、复杂偶联物、发夹 RNAs、高度修饰的寡核苷酸、免疫刺激序列、miRNA、比例双链体、sgRNA、siRNA
- 产品样本
-
Accelerate Your Journey from Clinic to Market
Produce high-quality oligo APIs and efficiently advance from clinic to market, delivering therapeutics to patients with unmet medical needs
- 产品样本
- English
- 2023 年 12 月 28 日
- 3.19 MB
- 宣传单页
视频
Agilent to Acquire North American CDMO BIOVECTRA
Agilent Technologies signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. This expands Agilent’s end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing.
- Agilent to Acquire North American CDMO BIOVECTRA
- 2024 年 7 月 22 日
Agilent Investing $725 Million to Expand State-of-the-Art Manufacturing Capacity for Production of Nucleic Acid-Based Therapeutics
Investment will double capacity to produce active pharmaceutical ingredients used in therapeutics for a broad range of diseases. The addition of two new manufacturing lines (known as Trains C and D) will enable Agilent to meet growing demand for siRNA, antisense and CRISPR guide RNA molecules. Agilent expects customer shipments from the expansion to begin in 2026.
- 2022 年 12 月 5 日